everolimus
information and resources from the National Cancer Institute
everolimus
A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. everolimus
A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production.
|
|
|
|
news articles
Guidant Delays New Stent Launch Mar 30, 2006
International News Service, The company has also stopped enrolling new patients in clinical trials of the Xience V Everolimus model, known as the Spirit III trial, which it had been ...
Nation & World Briefs Mar 29, 2006
Winston-Salem Journal, The company, based in Indianapolis, will also stop enrolling patients in a clinical trial for the Xience V Everolimus stent and has delayed the European debut ...
Updates, advisories and surprises Mar 29, 2006
Investor's Business Daily (subscription) ...the non-randomized portion of its Spirit III clinical trial, which is designed to evaluate the safety and efficacy of the Xience V Everolimus Eluting Coronary ...
Whirlpool-Maytag deal gets federal approval Mar 29, 2006
Minneapolis Star Tribune (subscription), The Indianapolis-based medical device maker also will stop enrolling patients in a clinical trial for the Xience V Everolimus stent and has delayed the ...
Es gibt keinen Besseren Mar 15, 2006
Finanzen.net, ...will support Guidant's PremarketApproval submission to the US Food and Drug Administration (FDA) forthe company's XIENCE(TM) V Everolimus Eluting Coronary ...
Guidant Won't Sell Drug-Coated Stents Mar 29, 2006
WJLA, ...medical device maker said Wednesday.The Indianapolis-based company also will stop enrolling patients in a clinical trial for the Xience V Everolimus stent and ...
Chest Service, Erasme University Hospital, Brussels, Belgium; and ... Mar 7, 2006
AJRCCM (subscription), ...cellular and cytokine profiles in endobronchial biopsies and/or bronchoalveaolar lavage fluid obtained in 13 patients treated with everolimus versus 10 ...
Taxus holds market share Mar 14, 2006
Pioneer Press, Eventually, the product will be offered with a different drug, everolimus, the rights to which Boston Scientific will obtain from Guidant after the merger, he ...
Guidant Announces Enrollment of First Patient in Clinical Trial of ... Mar 9, 2006
International News Service, ...announced enrollment of the first patient in a first-in-man clinical trial designed to evaluate the safety of a fully bioabsorbable everolimus eluting stent ...
Guidant Enrolls First Patient In Bioabsorbable Coronary Artery ... Mar 9, 2006
Trading Markets, ...solutions, announced that it has enrolled the first patient in a clinical trial to evaluate the safety of a fully bioabsorbable everolimus eluting stent ...
Guidant Finalizes Enrollment In Randomized US Portion Of Drug ... Mar 15, 2006
Trading Markets, According to the company, the randomized US cohort will support its Premarket Approval submission to the FDA for its XIENCE V Everolimus Eluting Coronary Stent ...
Guidant Reveals Results Of Clinical Trial, ABSORB - Quick Facts Mar 9, 2006
Trading Markets, GDT | charts | news | Powerrating) revealed results of clinical trial designed to evaluate the safety of a fully bioabsorbable everolimus eluting stent ...
Evaluation of Bioabsorbable Drug Eluting Coronary Stent Underway Mar 10, 2006
Medgadget.com, ...announced enrollment of the first patient into the ABSORB study, to evaluate the safety of Guidant's proprietary fully bioabsorbable everolimus eluting stent ...
Guidant Enrolls First Patient in Japan Arm of Drug Eluting Stent ... Dec 13, 2005
Genetic Engineering News, ...the company has begun enrollment in the Japan arm of its SPIRIT III drug eluting stent clinical trial evaluating XIENCE(TM) V, an everolimus eluting coronary ...
Boston Scientific trumps J&J bid for Guidant Dec 6, 2005
Pharma Times (subscription), Whichever company wins Guidant will bolster their franchise with the Xience V everolimus-eluting stent, which has just shown impressive efficacy in the 12 ...
DCGI may scrap Novartis' Certican clinical trials Nov 29, 2005
Business Standard, Certican (everolimus) is one of the latest drugs from Novartis’ portfolio to treat prophylaxis of organ rejection in adult patients receiving a heart or ...
|
|
